Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016

Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 - Global Markets Direct - Market Research
Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016
Published Jun 08, 2016
1200 pages — Published Jun 08, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Directs, Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016, provides an overview of the Kidney Cancer (Renal Cell Cancer) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kidney Cancer (Renal Cell Cancer), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kidney Cancer (Renal Cell Cancer) and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Kidney Cancer (Renal Cell Cancer)
- The report reviews pipeline therapeutics for Kidney Cancer (Renal Cell Cancer) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Kidney Cancer (Renal Cell Cancer) therapeutics and enlists all their major and minor projects
- The report assesses Kidney Cancer (Renal Cell Cancer) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Kidney Cancer (Renal Cell Cancer)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Kidney Cancer (Renal Cell Cancer)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising

  
Source:
Document ID
GMDHC8161IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents234
  List of Tables305
  List of Figures351
Introduction361
  Global Markets Direct Report Coverage361
Kidney Cancer (Renal Cell Cancer) Overview371
Therapeutics Development382
  Pipeline Products for Kidney Cancer (Renal Cell Cancer) Overview381
  Pipeline Products for Kidney Cancer (Renal Cell Cancer) Comparative Analysis391
Kidney Cancer (Renal Cell Cancer) Therapeutics under Development by Companies4011
Kidney Cancer (Renal Cell Cancer) Therapeutics under Investigation by Universities/Institutes512
Kidney Cancer (Renal Cell Cancer) Pipeline Products Glance534
  Late Stage Products531
  Clinical Stage Products541
  Early Stage Products551
  Unknown Stage Products561
Kidney Cancer (Renal Cell Cancer) Products under Development by Companies5718
Kidney Cancer (Renal Cell Cancer) Products under Investigation by Universities/Institutes752
Kidney Cancer (Renal Cell Cancer) Companies Involved in Therapeutics Development77146
  4SC AG771
  AbbVie Inc.781
  Acceleron Pharma, Inc.791
  Advanced Cancer Therapeutics801
  Advaxis, Inc.811
  Advenchen Laboratories, LLC821
  Alethia Biotherapeutics Inc.831
  Altor BioScience Corporation841
  Ambrx, Inc.851
  Amgen Inc.861
  Ampio Pharmaceuticals, Inc.871
  Apcure SAS881
  APEIRON Biologics AG891
  arGEN-X BV901
  Argos Therapeutics, Inc.911
  ArQule, Inc.921
  Arrowhead Pharmaceuticals, Inc.931
  Astellas Pharma Inc.941
  AstraZeneca Plc951
  ATLAB Pharma SAS961
  Aurigene Discovery Technologies Limited971
  Bayer AG981
  Berg LLC991
  BIND Therapeutics, Inc.1001
  Bio-Cancer Treatment International Limited1011
  BIOCAD1021
  Bionomics Limited1031
  Bionovis SA1041
  Boehringer Ingelheim GmbH1051
  Boston Biomedical, Inc.1061
  Bristol-Myers Squibb Company1071
  Caladrius Biosciences, Inc.1081
  Calithera Biosciences, Inc.1091
  CASI Pharmaceuticals Inc.1101
  Celgene Corporation1111
  Cellceutix Corporation1121
  Celldex Therapeutics, Inc.1131
  Celltrion, Inc.1141
  Cellular Biomedicine Group, Inc.1151
  Cerulean Pharma, Inc.1161
  Chipscreen Biosciences Ltd1171
  Clonz Biotech Private Limited1181
  Coare Biotechnology, Inc.1191
  Coherus BioSciences, Inc.1201
  Corcept Therapeutics Incorporated1211
  Corvus Pharmaceuticals, Inc.1221
  Cytune Pharma SAS1231
  Dr. Reddy's Laboratories Limited1241
  Ecrins Therapeutics SAS1251
  EirGenix Inc.1261
  Eisai Co., Ltd.1271
  Eli Lilly and Company1281
  Esperance Pharmaceuticals, Inc.1291
  Exelixis, Inc.1301
  F. Hoffmann-La Roche Ltd.1311
  Gene Techno Science Co., Ltd.1321
  Genor BioPharma Co., Ltd.1331
  GenSpera, Inc.1341
  GlaxoSmithKline Plc1351
  Glycotope GmbH1361
  HEC Pharm Co., Ltd.1371
  Horizon Pharma Plc1381
  Hutchison MediPharma Limited1391
  Immatics Biotechnologies GmbH1401
  Immune Design Corp.1411
  Immunicum AB1421
  ImmunoFrontier, Inc.1431
  ImmunoGen, Inc.1441
  Immunomedics, Inc.1451
  Incuron, LLC1461
  Incyte Corporation1471
  Innate Immunotherapeutics Ltd1481
  Johnson &Johnson1491
  KAHR medical Ltd.1501
  Karyopharm Therapeutics, Inc.1511
  KineMed, Inc.1521
  Komipharm International Co., Ltd.1531
  Kyowa Hakko Kirin Co., Ltd.1541
  Lead Discovery Center GmbH1551
  Mabion SA1561
  MacroGenics, Inc.1571
  MaxiVAX SA1581
  MediaPharma s.r.l.1591
  MedImmune, LLC1601
  Medivation, Inc.1611
  Merck &Co., Inc.1621
  Merck KGaA1631
  Millennium Pharmaceuticals, Inc.1641
  Mirati Therapeutics Inc.1651
  Mirna Therapeutics, Inc.1661
  Molecular Partners AG1671
  Mologen AG1681
  Monopar Therapeutics LLC1691
  Mycenax Biotech Inc.1701
  NanoSmart Pharmaceuticals, Inc.1711
  Nektar Therapeutics1721
  NewLink Genetics Corporation1731
  Novartis AG1741
  NovaTarg Therapeutics, Inc1751
  Omeros Corporation1761
  OncBioMune Pharmaceuticals Inc.1771
  Oncobiologics, Inc.1781
  Oncolys BioPharma Inc.1791
  OncoMax1801
  Ono Pharmaceutical Co., Ltd.1811
  Panacea Biotec Limited1821
  Peloton Therapeutics, Inc.1831
  Pfizer Inc.1841
  Pharmicell Co., Ltd.1851
  Pivotal BioSciences, Inc.1861
  Plexxikon Inc.1871
  Prima BioMed Ltd.1881
  PsiOxus Therapeutics Limited1891
  Qu Biologics Inc.1901
  Recombio S.L1911
  Rexahn Pharmaceuticals, Inc.1921
  Sanofi1931
  Seattle Genetics, Inc.1941
  Selvita S.A.1951
  Sevion Therapeutics, Inc.1961
  Shanghai Henlius Biotech Co., Ltd.1971
  Sillajen Biotherapeutics1981
  Sorrento Therapeutics, Inc.1991
  Sumitomo Dainippon Pharma Co., Ltd.2001
  Syndax Pharmaceuticals, Inc.2011
  Synthon Holdings BV2021
  Taiwan Liposome Company, Ltd.2031
  Takeda Pharmaceutical Company Limited2041
  Tara Immuno-Oncology Therapeutics LLC2051
  Taris Biomedical LLC2061
  TC BioPharm Limited2071
  Teva Pharmaceutical Industries Ltd.2081
  Theravectys SA2091
  Threshold Pharmaceuticals, Inc.2101
  Tocagen Inc.2111
  TRACON Pharmaceuticals, Inc.2121
  TVAX Biomedical, Inc.2131
  Tyrogenex, Inc.2141
  United BioPharma, Inc.2151
  UroGen Pharmaceuticals, Ltd.2161
  Vascular Biogenics Ltd.2171
  Vault Pharma Inc.2181
  Vaxeal Holding SA2191
  ViiV Healthcare Limited2201
  Vyriad2211
  X4 Pharmaceuticals, Inc.2221
Kidney Cancer (Renal Cell Cancer) Therapeutics Assessment22336
  Assessment by Monotherapy Products2231
  Assessment by Combination Products2241
  Assessment by Target22519
  Assessment by Mechanism of Action24411
  Assessment by Route of Administration2552
  Assessment by Molecule Type2572
Drug Profiles259942
  4SC-205 - Drug Profile2592
    Product Description2591
    Mechanism of Action2591
    R&D Progress2592
  9-ING41 - Drug Profile2611
    Product Description2611
    Mechanism of Action2611
    R&D Progress2611
  AB-3A4 - Drug Profile2621
    Product Description2621
    Mechanism of Action2621
    R&D Progress2621
  acalabrutinib - Drug Profile2633
    Product Description2631
    Mechanism of Action2631
    R&D Progress2633
  AdIL-24 - Drug Profile2662
    Product Description2661
    Mechanism of Action2661
    R&D Progress2662
  afatinib dimaleate - Drug Profile2685
    Product Description2681
    Mechanism of Action2681
    R&D Progress2685
  AGS-16C3F - Drug Profile2731
    Product Description2731
    Mechanism of Action2731
    R&D Progress2731
  AL-2846 - Drug Profile2741
    Product Description2741
    Mechanism of Action2741
    R&D Progress2741
  AL-3818 - Drug Profile2752
    Product Description2751
    Mechanism of Action2751
    R&D Progress2752
  AL-8326 - Drug Profile2771
    Product Description2771
    Mechanism of Action2771
    R&D Progress2771
  alpelisib - Drug Profile2782
    Product Description2781
    Mechanism of Action2781
    R&D Progress2782
  ALT-801 - Drug Profile2802
    Product Description2801
    Mechanism of Action2801
    R&D Progress2802
  ALT-803 - Drug Profile2823
    Product Description2821
    Mechanism of Action2821
    R&D Progress2823
  AM-0010 - Drug Profile2852
    Product Description2851
    Mechanism of Action2851
    R&D Progress2852
  amcasertib - Drug Profile2872
    Product Description2871
    Mechanism of Action2871
    R&D Progress2872
  ANDES-1230 - Drug Profile2891
    Product Description2891
    Mechanism of Action2891
    R&D Progress2891
  Andes-1560 - Drug Profile2901
    Product Description2901
    Mechanism of Action2901
    R&D Progress2901
  apatinib - Drug Profile2913
    Product Description2911
    Mechanism of Action2911
    R&D Progress2913
  APC-004 - Drug Profile2941
    Product Description2941
    Mechanism of Action2941
    R&D Progress2941
  APN-401 - Drug Profile2952

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016" Jun 08, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Kidney-Cancer-Renal-Cell-Cancer-Pipeline-Review-H1-2016-2088-15906>
  
APA:
Global Markets Direct - Market Research. (2016). Kidney Cancer (Renal Cell Cancer) - Pipeline Review, H1 2016 Jun 08, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Kidney-Cancer-Renal-Cell-Cancer-Pipeline-Review-H1-2016-2088-15906>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.